Schering-Plough Corporation, of Kenilworth, New Jersey, announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade® (infliximab) to include the treatment of early rheumatoid arthritis (RA), and has also approved a new indication for psoriatic arthritis (PsA). Remicade, in combination with methotrexate, can now be prescribed as first-line therapy for early RA. Remicade is also now indicated for the treatment of signs and symptoms of active PsA in adults with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs).

Remicade® is a chimeric IgG1 anti-TNF-alpha monoclonal antibody composed of human constant and murine variable regions administered by intravenous infusion.

— A. Techman